Protalix Biotherapeutics (NYSEAMERICAN:PLX) received a $5.00 target price from equities research analysts at HC Wainwright in a report issued on Wednesday. The firm presently has a “buy” rating on the stock.

Separately, Zacks Investment Research raised Protalix Biotherapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th.

Shares of Protalix Biotherapeutics (PLX) traded down $0.03 during trading on Wednesday, hitting $0.70. The stock had a trading volume of 1,127,900 shares, compared to its average volume of 1,876,003. Protalix Biotherapeutics has a twelve month low of $0.26 and a twelve month high of $1.51.

Protalix Biotherapeutics (NYSEAMERICAN:PLX) last announced its quarterly earnings data on Wednesday, November 8th. The company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.04). The firm had revenue of $7.53 million during the quarter, compared to analyst estimates of $6.65 million. During the same period last year, the business posted ($0.07) EPS.

A number of large investors have recently bought and sold shares of PLX. OxFORD Asset Management LLP acquired a new position in Protalix Biotherapeutics during the second quarter valued at $576,000. Virtu KCG Holdings LLC acquired a new position in Protalix Biotherapeutics during the second quarter valued at $591,000. Finally, Renaissance Technologies LLC raised its position in Protalix Biotherapeutics by 302.1% during the first quarter. Renaissance Technologies LLC now owns 1,927,500 shares of the company’s stock valued at $2,621,000 after buying an additional 1,448,200 shares during the period.

TRADEMARK VIOLATION NOTICE: This story was first reported by Daily Political and is the property of of Daily Political. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at

Protalix Biotherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease.

Receive News & Ratings for Protalix Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics Inc and related companies with's FREE daily email newsletter.